Category Archives: HIV/AIDS

International AIDS Conference 2012 in Washington DC abstract submissions open December 1

By on .

December 1 marks the opening of abstract submissions to the 2012 International AIDS Conference, which will be held in Washington DC in July.  Original contributions to the field in the following scientific tracks will be accepted: Track A: Basic Science Track B: Clinical Science Track C: Epidemiology and Prevention Science Track D: Social Science, Human […]

Vaginal gel arm of VOICE HIV prevention study halted

By on .

Another arm of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial has been discontinued, the National Institute of Allergy and Infectious Diseases at the National Institutes of Health announced Friday. The Data Safety Monitoring Board (DSMB) recommended the discontinuation of the daily one percent tenofovir vaginal gel arm of the study during […]

UNAIDS releases latest AIDS report

By on .

On Monday the Joint United Nations Program on HIV/AIDS (UNAIDS) released a new report on the state of global AIDS, which shows that nearly half of people living with HIV/AIDS who qualify for treatment are receiving it.  The 2011 UNAIDS World AIDS Day Report estimates that 6.6 million of the estimated 14.2 million people eligible […]

PEPFAR Scientific Advisory Board recommends accelerating scale up of HIV treatment

By on .

The Scientific Advisory Board (SAB) of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program met in September to discuss the results of the HIV Prevention Trials Network (HPTN) 052 trial, which found that individuals with HIV infection who were given immediate antiretroviral therapy (ART) were 96 percent less likely to transmit the virus […]

AIDS Clinical Trials Group teams up with TB Alliance to speed assessment of new TB treatment

By on .

The TB Alliance announced Tuesday that it has enlisted the help of the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trial Group (ACTG) to help complete testing of a potentially shorter tuberculosis treatment regimen utilizing an antibiotic not currently registered to treat TB – moxifloxacin.

Young investigators unearth important discoveries in global health

By on .

Young investigators and Fogarty students presented select posters on global health at a special gallery during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Boston last month. The event was sponsored by the National Insitutes of Health Office of AIDS Research, the Accordia Global Health Foundation and the IDSA Education and Research Foundation. In this video interview, Sten Vermund, MD, PhD, director of the Institute for Global Health at Vanderbilt University, discusses one of the student “highlights” of the evening – Krutika Kuppalli, MD, from the University of California, San Diego – and her research on HIV and leptospirosis in Chenai, India.

AIDS docs debate how and when to scale up treatment as prevention

By on .

In the sixth in a series of debates about the world’s HIV response hosted by the World Bank and USAID, physician-scientists debated how best to transform the exciting results from the HPTN) 052 study, which demonstrated that those with HIV infection who received immediate treatment with antiretroviral therapy (ART) were 96 percent less likely to transmit HIV to their uninfected sexual partners than those whose treatment was delayed. The panelists were tasked with debating not only how to apply treatment as prevention (TasP) quickly, and how to add it to the combination prevention tool kit effectively, but more so whether or not it makes sense to have countries spend a majority of what is likely to be a flat or declining HIV prevention budget on TasP.

AIDS advocacy groups call on legislators to end AIDS

By on .

“We can begin to end the AIDS epidemic. Will we?”

AIDS advocacy groups took out a full page advertisement in the print edition of Thursday’s Politico. Utilizing quotes from political, scientific and religious leaders, the groups sent the message that we now have the tools to begin to end the AIDS epidemic – but will we follow through?